The safety and efficacy of chemotherapy combined with immunotherapy for pancreatic cancer

A meta-analysis

Yang Huang, MD, Xu Yan, MD, Tian Ren, MD, Fan Yi, MD, Qi Li, MD, Chunyang Zhang, MD∗

Abstract

Background: Since the combination of chemotherapy and immunotherapy, such as new molecular targeted drugs or vaccines, is controversial in terms of survival advantages compared with chemotherapy therapy alone, we conducted a meta-analysis to compare the efficacy and safety of immunotherapy combined with chemotherapy and chemotherapy alone for advanced pancreatic cancer.

Methods: We searched PubMed, Embase, and Cochrane Library from the establishment of the database to November 2020. We included some studies that reported pancreatic cancer patients receiving immunotherapy, and we excluded duplicate publications, research without full text, incomplete information or inability to conduct data extraction, animal experiments, reviews, and systematic reviews.

Results: The risk ratio of the objective response rate and disease control rate was 1.10 (95% confidence interval [CI]: 0.88–1.38) and 1.17 (95% CI: 1.06–1.31), respectively, indicating that there was no significant difference between the objective response rate of combination therapy and chemotherapy alone, while the disease control rate of the combined treatment was higher than that of chemotherapy alone. The hazard ratio of overall survival and progression-free survival was 0.91 (95% CI: 0.82–1.01) and 0.87 (95% CI: 0.77–0.98), respectively, indicating that there was no significant difference between the overall survival of combination therapy and chemotherapy alone, while progression-free survival of the combined treatment was longer than that of chemotherapy alone. We also found that in addition to the combination treatment, the incidence of vomiting in pancreatic cancer was higher than that of chemotherapy alone, and the incidence of other complications was not significantly different from that of treatment alone.

Conclusion: Chemotherapy combined with immunotherapy for pancreatic cancer not only improves treatment efficiency but also does not cause serious adverse reactions. This treatment strategy should be widely used clinically.

Abbreviations: AEs = adverse events, CI = confidence interval, DCR = disease control rate, GEM = Gemcitabine, HR = hazard ratio, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, RCTs = randomized controlled trials, RR = risk ratio.

Keywords: chemotherapy, combination therapy, immunotherapy, meta-analysis, pancreatic cancer

1. Introduction

Pancreatic cancer is the fourth leading cause of cancer-related deaths worldwide, with a 5-year survival rate of <9%. Most patients with pancreatic cancer are diagnosed with unresectable advanced disease and die from the disease within 1 year.[1] Therefore, most patients require adjuvant therapy, such as radiotherapy and chemotherapy. Chemotherapy is known to prolong the survival of patients with advanced pancreatic cancer.[2,3] Although cytotoxic drugs are generally believed to have immunosuppressive effects, certain chemotherapies may enhance the effects of cancer vaccines.[4–8] Gemcitabine (GEM) and fluorouracil induce apoptosis of cancer cells, leading to the release of antigens, which can be absorbed by professional antigen-presenting cells and cross-presented to cytotoxic T cells.[9] The guidelines have recommended GEM monotherapy as the first-line treatment for unresectable locally advanced metastatic ductal carcinoma of the pancreas since 1997.[10] With the continuous emergence of single chemotherapy treatment failures, it is becoming increasingly important to explore new combination regimens.
Several large clinical randomized controlled trials (RCTs) have been implemented to further observe the effectiveness and safety of GEM-based combination therapy.\(^{11}\) In addition, FOLFIRINOX, 5-fluouracil, Abraxane, and other chemotherapeutics other than GEM can also be used to treat pancreatic cancer. In recent years, immunotherapy, including PD1/PDL1 and CTLA-4 immune checkpoint inhibitors, has become more widely used in pancreatic cancer.\(^{12}\) However, the combination of chemotherapy and immunotherapy, such as new molecular targeted drugs or vaccines, is controversial in terms of survival advantages compared with chemotherapy alone. Therefore, more representative results are needed to compare the efficacy and safety of immunotherapy combined with chemotherapy and chemotherapy alone, to provide guidance for current clinical treatment. In this meta-analysis, we compared the efficacy and safety of immunotherapy combined with chemotherapy and chemotherapy alone for advanced pancreatic cancer.

2. Methods

2.1. Literature inclusion and exclusion criteria

Inclusion criteria were limited to RCTs and language was limited to English. Exclusion criteria include as follows: repetitive publication; study without full text, incomplete information, or data extraction is impossible; and the definition of exposure is quite different from most of the literature and the incomplete ethics review.

2.2. Search strategy

We searched PubMed, Embase, and Cochrane Library. The search period was from the establishment of the database until November 2020. The combination of subject words and free terms was used to search for the search terms. Search terms included “pancreatic neoplasms” “pancreas cancers” “pancreatic carcinoma” “pancreatic cancers,” and “immunotherapy” “pembrolizumab” “tremelimumab” “avelumab” “cetuximab” “bevacizumab” “erlotinib,” and “chemotherapy” “FOLFIRINOX” “5-FU,” and “Abraxane.”

2.3. Literature screening and data extraction

The literature search, screening, and information extraction were independently completed by 2 researchers. When there were doubts or disagreements, the decision or consultation with a third party was made after discussion. The content of data extraction included author, year, country, research type, number of cases, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS).

2.4. Literature quality assessment

Two researchers independently conducted the literature quality assessment according to the Cochrane risk assessment scale. When opinions are inconsistent, it is decided through a discussion or consultation with a third person. The meta-analysis was performed based on the items related to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement (PRISMA statement).\(^{13}\)

2.5. Statistical methods

The data were analyzed using Review Manager version 5.3. Risk ratio (RR) was used to compare the ORR and DCR of the 2 groups, and hazard ratio (HR) (95% confidence interval [CI]) was used to assess PFS and OS. If the heterogeneity test was \(P \geq .1, I^2 \leq 50\%\), the fixed-effect model was used for the combined analysis; if \(P < .1, I^2 > 50\%\), the random effect model was used for the combined analysis, and sensitivity analysis and meta-regression were used to explore sources of heterogeneity when necessary. Since the number of articles in this study was less than 10, no publication bias was discussed.

3. Results

3.1. The results of the literature search

In this study, 1177 studies were retrieved from the database. After eliminating duplicate studies, a total of 837 patients were obtained. After browsing the titles and abstracts, 681 studies were conducted. Finally, after the full-text reading, 8 articles were included in the meta-analysis (Fig. 1).

3.2. Baseline characteristics and quality assessment of the included studies

3.2.1. Baseline characteristics. Eight RCT studies were included in this meta-analysis. The sample size ranged from 84 to 743, and a total of 2547 patients were included in the present meta-analysis. Patients in 2 studies were from Asia, while the others were from Europe and America (Table 1).

3.2.2. Quality assessment of the included studies. The quality assessment of these included studies are shown in Figures 2 and 3.

3.3. Results of meta-analysis

3.3.1. Efficacy analysis. Six studies, including 2223 patients, reported the RR of the ORR. Since there was no significant heterogeneity \((I^2 = 0.0\%, P = .55 > .1)\), a meta-analysis was conducted using a fixed-effects model. The RR of ORR was 1.10 (95% CI: 0.88–1.38), indicating that there was no significant difference between the ORR of combination therapy and chemotherapy alone (Fig. 4A).

Five studies, including 1554 patients, reported the RR of DCR. Since there was no significant heterogeneity \((I^2 = 0.0\%, P = .51 > .1)\), a meta-analysis was conducted using a fixed-effects model. The RR of DCR was 1.17 (95% CI: 1.06–1.31), indicating that the DCR of the combined treatment was higher than that of chemotherapy alone (Fig. 4B).

Six studies, including 1777 patients, reported the HR of OS. Since there was no significant heterogeneity \((I^2 = 6\%, P = .380.1)\), a meta-analysis was conducted using a fixed-effects model. The HR of OS was 0.91 (95% CI: 0.82–1.01), indicating that there was no significant difference between the OS of combination therapy and chemotherapy alone (Fig. 4C).

Four studies, including 1022 patients, reported the HR of PFS. Since there was no significant heterogeneity \((I^2 = 50\%, P = .110.1)\), a meta-analysis was conducted using a fixed-effects model. The HR of PFS was 0.87 (95% CI: 0.77–0.98), indicating that the PFS of the combined treatment was longer than that of chemotherapy alone (Fig. 4D).

3.3.2. Incidence of adverse events. Among all studies, 7 were included in the analysis of grade \(\geq 3\) adverse events. Moreover,
Table 1
Baseline characteristics of the included studies.

| Author          | Year | Country | Research type | Number of cases | Median follow-up time (months) | Combined therapy | Chemotherapy | Combined therapy | Chemotherapy | Combined therapy | Chemotherapy | Measures of combined therapy |
|-----------------|------|---------|----------------|-----------------|-------------------------------|------------------|--------------|------------------|--------------|------------------|--------------|--------------------------------|
| Cascini et al   | 2008 | Italy   | RCT            | 11.8            | 42/42                         | 61.0 (38.0–78.0) | 64.0 (40.0–76.0) | 29/13            | 22/20        | Gemcitabine + Cetuximab           |
| Philip et al    | 2010 | Canada  | RCT            | /               | 372/371                       | 63.7             | 64.3         | 51/79            | 54/46        | Gemcitabine + Cetuximab           |
| Kindler et al   | 2010 | United States | RCT          | 12              | 302/300                       | 63.7 (26.0–88.0) | 65.0 (35.0–86.0) | 175/127          | 168/162      | Gemcitabine + Bevacizumab         |
| Wang et al      | 2013 | China   | RCT            | /               | 28/30                         | 50.26            | 50.22        | 15/13            | 16/14        | S-1 + CIK                             |
| Middleton et al | 2014 | United Kingdom | RCT          | 6               | 354/358                       | 62.0 (55.0–69.0) | 63.0 (57.0–69.0) | 196/158          | 209/149      | Gemcitabine + GVAX               |
| Yamaue et al    | 2015 | Japan   | RCT            | 3.7             | 100/53                        | 63.5 (38.0–80.0) | 65.0 (36.0–80.0) | 62/38            | 31/22        | Gemcitabine + Elpamotide          |
| Daigleish et al | 2016 | United Kingdom | RCT          | 6.7             | 75/35                         | 68.0 (45.0–88.0) | 66.0 (53.0–83.0) | 38/37            | 21/14        | Gemcitabine + IMM-101             |
| Nishida et al   | 2018 | Japan   | RCT            | 12              | 42/43                         | 66.0 (37.0–77.0) | 69.0 (43–77)  | 26/16            | 25/18        | Gemcitabine + WT1                |

RCTs = randomized controlled trials.
studies with insufficient data were excluded from the analysis. The pooled RR of diarrhea, nausea, vomiting, and increased ALT and AST between the combined treatment group and chemotherapy group were 1.09 (95% CI: 0.64–1.88; $I^2 = 0$), 1.31 (95% CI: 0.91–1.88; $I^2 = 0$), 1.54 (95% CI: 0.72–2.56; $I^2 = 0$), and 1.52 (95% CI: 0.54–4.27; $I^2 = 0$), respectively (Fig. 5). The results showed that the incidence of vomiting in combination therapy was higher than that in the chemotherapy alone, and the incidence of other complications was not significantly different from that of chemotherapy alone.

3.4. Publication bias

A funnel plot of this study is shown in Figure 6. It can be seen that the funnel plot is basically symmetrical, indicating that there is no obvious publication bias in this study.

3.5. Sensitivity analysis

Sensitivity analysis eliminates each included study one by one and performs a summary analysis on the remaining studies to assess whether a single included study has an excessive impact on the results of the entire meta-analysis. The results showed that none of the studies had an excessive impact on the results of the meta-analysis, indicating that the results of the remaining studies were stable and reliable.

3.6. Discussion

GEM, FOLFIRINOX, 5-fluorouracil, Abraxane, and other chemotherapeutics have been commonly used to treat pancreatic cancer. In recent years, immunotherapy, including PD1/PDL1 and CTLA-4 immune checkpoint inhibitors, has become more widely used in pancreatic cancer.\(^\text{12}\) However, the combination of chemotherapy and immunotherapy, such as new molecular targeted drugs or vaccines, is controversial in terms of survival advantages compared with chemotherapy alone, and we conducted a meta-analysis to compare the efficacy and safety of immunotherapy combined with chemotherapy and chemotherapy alone for advanced pancreatic cancer. In this meta-analysis, we included 8 articles involving 2547 patients.

Pancreatic cancer is characterized by early local regional spread and distant metastasis. Most patients cannot be cured by surgical resection when they are diagnosed, and without effective treatment, the overall median survival time is 4.6
months, especially in patients with metastatic cancer, with a median survival time of 2.8 to 5.7 months. Our pooled results showed that the DCR of the combined treatment was higher than that of chemotherapy alone (RR = 1.17, 95% CI: 1.06–1.31) and the PFS of the combined treatment was longer than that of chemotherapy alone (HR = 0.87, 95% CI: 0.77–0.98). Cancer immunotherapy is a promising strategy for treating pancreatic cancer. Unfortunately, immunotherapy in large or late clinical trials failed to show satisfactory clinical results, which can be expected in some early studies. So far, immune checkpoint inhibitors, including anti-PD1/PDL1 and CTLA-4, have also failed to achieve the desired goal. The relative absence of immunotherapy efficacy in pancreatic cancer might also partly be related to specific carcinoma-associated fibroblasts, which secrete CXCL12 and thus stop T cells from accessing cancer cell regions in the stroma. Considering the difficulty of developing cancer immunotherapies for pancreatic cancer, our pooled results provide a way to increase the anti-tumor response of patients. We also explored the safety of the combination therapy. Findings show that in addition to the combination treatment, the incidence of pancreatic cancer vomiting was higher than that of
chemotherapy alone, and the incidence of other complications was not significantly different from that of treatment alone. This also strengthens our confidence in the use of combination therapies for pancreatic cancer.

This meta-analysis had some limitations. Since the number of included articles was less than 10, we did not carry out Egger bias test, which may have led to some potential publication bias.

Future studies need to include more RCTs to further verify our pooled results.

3.7. Conclusion

Chemotherapy combined with immunotherapy for pancreatic cancer can not only improve treatment efficiency but also will not
cause serious adverse reactions. This treatment strategy should be widely used clinically.

**Author contributions**

Yang Huang conceived the study and wrote the manuscript. Xu Yan and Tian Ren provided the direction. Fan Yi and Qi Li participated in data collection. Chunyang Zhang conceived the final approval of the version to be submitted and obtaining of funding.

**Conceptualization:** Yang Huang.

**Data curation:** Xu Yan, Tian Ren, Fan Yi, Qi Li.

**Writing – original draft:** Yang Huang.

**Writing – review & editing:** Chunyang Zhang.

**References**

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. Epub 2019/01/09. doi: 10.3322/caac.21551. PubMed PMID: 30620402.

[2] Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 2010;14:386–94. Epub 2010/05/26. PubMed PMID: 20496533.

[3] Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073–81. Epub 2010/09/09. doi: 10.1001/jama.2010.1275. PubMed PMID: 20823433.

[4] Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-presentation rather than cross-tolerizing host tumor-specific CD8T cells. J Immunol 2003;170:4905–13. Epub 2003/05/08. doi: 10.4049/jimmunol.170.10.4905. PubMed PMID: 12734333.

[5] Fridlender ZG, Sun J, Singhal S, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immunemediated mechanisms. Mol Ther 2010;18:1947–59. Epub 2010/08/05. doi: 10.1038/mt.2010.159. PubMed PMID: 20683443; PubMed Central PMCID: PMCPMC2990510.

[6] Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010;102:115–23. Epub 2009/12/10. doi: 10.1038/sj.bjc.6605465. PubMed PMID: 19997099; PubMed Central PMCID: PMCPMC2813751.

[7] Suzuki E, Kapoor AS, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713–21. Epub 2005/09/17. doi: 10.1158/1078-0432.CCR-05-0883. PubMed PMID: 16166452.

[8] Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011;129:832–8. Epub 2011/06/29. doi: 10.1002/ijc.25756. PubMed PMID: 21710545.

[9] Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003;14:833–43. Epub 2003/11/05. doi: 10.1097/00001813-200311000-00010. PubMed PMID: 14597879.

[10] Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 2010;23:1183–92. Epub 2010/04/08. doi: 10.3892/or_00000749. PubMed PMID: 20372829.

[11] Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002;29(6 Suppl 20):9–16. Epub 2003/02/11. doi: 10.1053/sonc.2002.37372. PubMed PMID: 12577228.

[12] Lee MJ, Park SW, Park HS, et al. Gemcitabine and cisplatin for advanced pancreatic cancer: a meta-analysis of published randomized trials. Int J Cancer 2003;104:551–60. Epub 2002/11/07. doi: 10.1002/ijc.11311. PubMed PMID: 12441024.

[13] Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2008;26:479–86. Epub 2008/01/01. doi: 10.1200/JCO.2007.12.4484. PubMed PMID: 18105705; PubMed Central PMCID: PMCPMC2137164.

[14] Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus nab-paclitaxel versus gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605–10. Epub 2009/11/23. doi: 10.1200/JCO.2009.25.3953. PubMed PMID: 19943011; PubMed Central PMCID: PMCPMC2792150.

[15] Rettig L, Seidenberg S, Parvanova I, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011;129:832–8. Epub 2011/06/29. doi: 10.1002/ijc.25756. PubMed PMID: 21710545.

[16] Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003;14:833–43. Epub 2003/11/05. doi: 10.1097/00001813-200311000-00010. PubMed PMID: 14597879.

[17] Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 2010;23:1183–92. Epub 2010/04/08. doi: 10.3892/or_00000749. PubMed PMID: 20372829.

[18] Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002;29(6 Suppl 20):9–16. Epub 2003/02/11. doi: 10.1053/sonc.2002.37372. PubMed PMID: 12577228.

[19] Lee MJ, Park SW, Park HS, et al. Gemcitabine and cisplatin for advanced pancreatic cancer: a meta-analysis of published randomized trials. Int J Cancer 2003;104:551–60. Epub 2002/11/07. doi: 10.1002/ijc.11311. PubMed PMID: 12441024.

[20] Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2008;26:479–86. Epub 2008/01/01. doi: 10.1200/JCO.2007.12.4484. PubMed PMID: 18105705; PubMed Central PMCID: PMCPMC2137164.

[21] Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus nab-paclitaxel versus gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605–10. Epub 2009/11/23. doi: 10.1200/JCO.2009.25.3953. PubMed PMID: 19943011; PubMed Central PMCID: PMCPMC2792150.
2010/07/08. doi: 10.1200/JCO.2009.25.7550. PubMed PMID: 20606093; PubMed Central PMCID: PMCPMC2917315.

[16] Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617–22. Epub 2010/07/08. doi: 10.1200/JCO.2010.28.1386. PubMed PMID: 20606091; PubMed Central PMCID: PMCPMC2917317.

[17] Wang M, Shi SB, Qi JL, Tang XY, Tian J. S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 2013;30:747. Epub 2013/10/15. doi: 10.1007/s12032-013-0747-9. PubMed PMID: 24122257.

[18] Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 2014;15:829–40. Epub 2014/06/24. doi: 10.1016/S1470-2045(14)70236-0. PubMed PMID: 24954781.

[19] Yamaue H, Tsunoda T, Tani M, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 2015;106:883–90. Epub 2015/04/14. doi: 10.1111/cas.12674. PubMed PMID: 25867139; PubMed Central PMCID: PMCPMC4520640.

[20] Dalgleish AG, Stebbing J, Adamson DJ, et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 2016;115:e16. Epub 2016/10/26. doi: 10.1038/bjc.2016.342. PubMed PMID: 2772733; PubMed Central PMCID: PMCPMC5117801.

[21] Nishida S, Ishikawa T, Egawa S, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study. Cancer Immunol Res 2018;6:320–31. Epub 2018/01/24. doi: 10.1158/2326-6066.CIR-17-0386. PubMed PMID: 29358173.

[22] Dalgleish AG, Stebbing J, Adamson DJ, et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 2016;115:e16. Epub 2016/10/26. doi: 10.1038/bjc.2016.342. PubMed PMID: 2772733; PubMed Central PMCID: PMCPMC5117801.

[23] Salman B, Zhou D, Jaffe EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology 2013;2:e26662Epub 2014/02/06. doi: 10.4161/onci.26662. PubMed PMID: 2449551; PubMed Central PMCID: PMCPMC3912009.

[24] Jimenez-Luna C, Prados J, Ortiz R, Melguizo C, Torres C, Cabo O. Current status of immunotherapy treatments for pancreatic cancer. J Clin Gastroenterol 2016;50:836–48. Epub 2016/08/10. doi: 10.1097/MCG.0000000000000623. PubMed PMID: 27505403.

[25] Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol 2016;22:9457–76. Epub 2016/12/07. doi: 10.3748/wjg.v22.i43.9457. PubMed PMID: 27920468; PubMed Central PMCID: PMCPMC5116591.

[26] Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013;110:20212–7. Epub 2013/11/28. doi: 10.1073/pnas.1320318110. PubMed PMID: 24277834; PubMed Central PMCID: PMCPMC3864274.

[27] Sorrentino C, Miele L, Porta A, Pinto A, Morello S. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget 2016;7:64274–88. Epub 2016/09/04. doi: 10.18632/oncotarget.11729. PubMed PMID: 27590304; PubMed Central PMCID: PMCPMC5325441.